REZOLUTE INC. - COMMON STOCK (NV)

Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting

23 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

06 Mar 2024 06:30:00 By Nasdaq GlobeNewswire

Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

13 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer

24 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

23 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism

14 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)

13 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day

17 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Rezolute Reports First Quarter Fiscal 2024 Results

13 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism

17 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism

11 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress

14 Sep 2023 15:05:00 By Nasdaq GlobeNewswire

Rezolute to Participate in Upcoming Investor Conferences in September

06 Sep 2023 06:00:00 By Nasdaq GlobeNewswire

Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism

27 Jun 2023 15:05:00 By Nasdaq GlobeNewswire

Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress

11 May 2023 15:05:01 By Nasdaq GlobeNewswire

Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema

23 Mar 2023 15:50:08 By Nasdaq GlobeNewswire

Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert

08 Mar 2023 06:00:02 By Nasdaq GlobeNewswire

Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress

10 Feb 2023 15:05:00 By Nasdaq GlobeNewswire

Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema

15 Dec 2022 06:00:00 By Nasdaq GlobeNewswire

Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress

09 Nov 2022 15:05:02 By Nasdaq GlobeNewswire